Twist Bioscience Expands Expert Custom Alliance Panel Offering
October 05 2021 - 7:00AM
Business Wire
- Ready to Order Clinically Validated,
Expert-Designed Panels Offer Important Tools for Multiple Research
Applications –
- Twist Alliance Pan-Cancer Methylation Panel
Launched -
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced an expansion of its
expert-led Alliance Panel product offering. Designed through
collaboration with world-leading experts, Twist Alliance Panels
combine validated content with Twist next-generation sequencing
(NGS) workflow, target enrichment and DNA probes. In an extension
of Twist’s OEM strategy, Twist will market products designed by key
opinion leaders in a wide range of clinical applications and
powered by Twist tools through the Alliance Panel program. In
return, expert collaborators receive a royalty on the sale of
products and will carry partner branding.
“Data generated and validated by experts around the world bring
incredible value to the research community,” said Emily M.
Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “By
working together, we are leveraging this extensive knowledge,
providing the global community with better research tools, all
powered by Twist products, and also ensuring the experts involved
receive recognition and royalties for their hard work.”
As the first Alliance Panel offering, Twist collaborated with
the Regeneron Genetics Center LLC (RGC), a wholly-owned subsidiary
of Regeneron, to develop the Twist Diversity SNP Panel, a custom
NGS population genetics genotyping assay available to researchers
globally for population genomics studies.
Today, Twist and AnchorDx launched the Twist Alliance Pan-cancer
Methylation Panel based on The Cancer Genome Atlas (TCGA) database,
including 31 cancer types and 47 TCGA database disease entities.
The pan-cancer profile saves customers sequencing costs and reduces
the complexity of analysis. Validation studies were conducted using
tumor biopsy samples from breast cancer, colorectal cancer and
non-small cell lung cancer. DNA methylation regions included in the
panel have been found to clearly differentiate cancer tissues from
the non-malignant tissue in these three cancer types, among the
most common cancers.
About Twist Alliance Panels
In partnership with leading research institutions from around
the world, Twist has curated a collection of high-quality target
enrichment panels for applications ranging from carrier screening
to cancer diagnostics and whole exome sequencing. The Twist
Alliance Panels combine the strengths of precise, highly uniform
oligonucleotide synthesis with the specialty expertise of leading
scientific research partners.
Well designed, custom target enrichment panels enable increased
sequencing depth on target genes while reducing overall sequencing.
This allows for more sensitive detection of target sequences and
higher confidence variant detection.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; the retention
of employees of acquired companies and the ability of Twist
Bioscience to successfully integrate acquired companies and to
achieve expected benefits, risks of third party claims alleging
infringement of patents and proprietary rights or seeking to
invalidate Twist Bioscience’s patents or proprietary rights; and
the risk that Twist Bioscience’s proprietary rights may be
insufficient to protect its technologies. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to Twist Bioscience’s business in general,
see Twist Bioscience’s risk factors set forth in Twist Bioscience’s
Quarterly Report Form 10-Q filed with the Securities and Exchange
Commission on August 9, 2021 and subsequent filings with the SEC.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211005005476/en/
Twist Bioscience Angela Bitting SVP, Corporate Affairs
925- 202-6211 media@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024